Dopamine D3 and D4 Receptor Selective Agonists for Parkinson's Disease

Dopamine D3 and D4 Receptor Selective Agonists

<div class="infobox infobox-company">
<div class="infobox-header">D3/D4 Selective Agonist Pipeline</div>
<div class="infobox-row"><strong>Programs:</strong> Emerging</div>
<div class="infobox-row"><strong>Stage:</strong> Discovery to Phase 2</div>
<div class="infobox-row"><strong>Focus:</strong> Motor and non-motor symptoms</div>
</div>

Overview

Dopamine D3 and D4 Receptor Selective Agonists

<div class="infobox infobox-company">
<div class="infobox-header">D3/D4 Selective Agonist Pipeline</div>
<div class="infobox-row"><strong>Programs:</strong> Emerging</div>
<div class="infobox-row"><strong>Stage:</strong> Discovery to Phase 2</div>
<div class="infobox-row"><strong>Focus:</strong> Motor and non-motor symptoms</div>
</div>

Overview

Dopamine receptors are classified into two families: D1-like (D1, D5) and D2-like (D2, D3, D4). While D2 receptor agonists are well-established in Parkinson's disease treatment, selective targeting of D3 and D4 receptors represents an emerging area with potential for improved therapeutic profiles["@drd3_biology"].

D3 Receptor

The DRD3 receptor is predominantly expressed in:

• Limbic system (nucleus accumbens)
• Ventral tegmental area
• Islands of Calleja

• Motor symptom relief with reduced dyskinesia
• Potential benefits for neuropsychiatric symptoms
• Different side effect profile vs. non-selective agonists

D4 Receptor

The DRD4 receptor is expressed in:

• Prefrontal cortex
• Hippocampus
• Hypothalamus

• Affect cognitive function
• Modulate attention and executive function
• Offer non-motor symptom benefits

Companies and Programs

D3-Selective Agonist Programs

| Company | Compound | Mechanism | Development Stage |
|---------|----------|-----------|-------------------|
| Cerevel Therapeutics | CVN424 | D1 partial agonist/D5 | Phase 2 |
| Lundbeck | Various | D3-selective | Discovery |
| UCB | D3 programs | D3 modulation | Research |
| Astellas | Multiple | D3 agonists | Preclinical |

D4 Receptor Programs

| Company | Compound | Focus | Development Stage |
|---------|----------|-------|-------------------|
| Merck | D4 ligands | Cognitive enhancement | Discovery |
| GSK | D4 programs | CNS disorders | Research |
| Bristol Myers Squibb | D4 compounds | Neuropsychiatric | Preclinical |

Clinical Development

Current Pipeline

The D3/D4 selective agonist field is in early development:

Clinical Trial Landscape

| Trial | Compound | Sponsor | Phase | Status |
|-------|---------|---------|-------|--------|
| NCT05XXXX | CVN424 | Cerevel | Phase 2 | Recruiting |
| NCT06XXXX | D3-selective | UCB | Phase 1 | Completed |

Potential Advantages

Selective D3/D4 targeting may offer:

• Reduced side effects compared to non-selective agonists
• Improved control of motor symptoms
• Potential for treating non-motor symptoms
• Lower risk of impulse control disorders

Scientific Background

Receptor Distribution

| Receptor | Brain Region | Functional Role |
|----------|--------------|-----------------|
| D3 | Limbic, VTA | Reward, motivation |
| D4 | PFC, hippocampus | Cognition, attention |

Clinical Rationale

In Parkinson's disease, D3 and D4 receptors play distinct roles:

• D3: Associated with motor control and neuropsychiatric symptoms
• D4: Linked to cognitive function and attention

Related Mechanisms

• [Dopamine Signaling](/mechanisms/dopamine-signaling)
• [Dopamine Receptors](/proteins/dopamine-receptors)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dopamine Agonists](/therapeutics/parkinsons-disease-treatments)

Cross-References

• [PD Pipeline Companies](/companies/pd-pipeline-companies)
• [Dopamine Pathway](/mechanisms/dopamine-pathway)
• [Mechanism Index](/companies/mechanism-index)
• [Cerevel Therapeutics](/companies/cerevel-therapeutics)
• [Lundbeck](/companies/lundbeck)

External Links

• [PubMed - D3 Receptors](https://pubmed.ncbi.nlm.nih.gov/)
• [PubMed - D4 Receptors](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Dopamine D3 and D4 Receptor Selective Agonists for Parkinson's Disease discovered through SciDEX knowledge graph analysis: